On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International  Congress of the Asian Oncology Society (AOS2024) . This esteemed event will be held from November 14-16, 2024, in the historic and culturally rich city of Xi'an, China, the birthplace of Holistic Integrative Medicine. The 2024 CCHIO is proudly sponsored by the China Anti-Cancer Association and co-organized by the Shaanxi Anti-Cancer Association, and the China Research Institute of Development Strategies of Holistic Integrative Medicine.

On October 18-19, 2024, the CACA Integrated Gastric Cancer Conference concluded successfully in Wuhan, gathering global authorities in gastric cancer to discuss the latest advancements, pioneering developments, and standardized protocols for gastric cancer treatment. During the event, the Chinese Anti-Cancer Association Gastric Cancer Professional Committee (CGCA) completed its transition, electing Dr. Lin Chen from Peking University International Hospital as the new Chairman.Oncology Frontier had the privilege to conduct an in-depth interview with Dr. Lin Chen at the conference to discuss the future priorities and development strategies for the CGCA.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting is taking place from September 13-17 in Barcelona, Spain. Dr. Tao Sun from Liaoning Cancer Hospital is leading a prospective phase II study, which will be presented as a poster at the conference (Poster Abstract No. 387P). This study explores the efficacy and safety of the combination of anlotinib, penpulimab, and nab-paclitaxel as first-line treatment for advanced triple-negative breast cancer (TNBC). The interim results demonstrate the significant advantages of this combination in terms of objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS), while also confirming its favorable safety and tolerability. As the research progresses, we anticipate that this innovative therapy could further extend patient survival and improve quality of life, offering hope to more TNBC patients.

Recently, the "Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2024 Edition)" was published, co-authored by Academician Jinming Yu of Shandong Cancer Hospital, Professor Ying Cheng of Jilin Cancer Hospital, and Professor Liangan Chen of the Chinese People’s Liberation Army General Hospital. This publication marks a new level of scientific standardization in the multidisciplinary management of radiotherapy and immunotherapy.Oncology Frontier invited Dr. Yong Song from the Department of Respiratory Medicine, Jinling Hospital, Nanjing University Medical School, one of the core reviewers of the consensus expert group, to share his insights on the consensus guidelines for managing adverse reactions from a respiratory perspective.

Four international experts will jointly chair the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC), scheduled to take place in Barcelona from September 6 to 9, 2025. Here is an introduction to the incoming co-chairs who will guide the planning of WCLC 2025 and serve as ambassadors to the global attendees.

The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain. As an annual highlight in the oncology field, ESMO attracts thousands of leading oncologists from around the world, providing a rich platform for global academic exchange. This year, multiple studies from Dr. Dingwei Ye’s team at Fudan University Shanghai Cancer Center were selected for presentation at ESMO. Among them, Professor Ye led the study on "BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)," which received significant attention and discussions, showcasing Chinese expertise and innovation in urologic oncology on a global scale. Urology Frontier had the pleasure of inviting Professor Ye to share his insights on these landmark studies.

On October 19-20, 2024, the first stop of the "St. Gallen Breast Cancer Conference (SGBCC) China Tour" was held in Nanjing. This series of events, organized by the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), the Beijing CSCO Clinical Oncology Research Foundation, the Beijing Kexin Medical Development Foundation, and the Jiangsu Anti-Cancer Association, and hosted by Jiangsu Provincial  Hospital, facilitated the exchange of knowledge between Chinese and foreign experts and laid the foundation for updating the new "St. Gallen International Expert Consensus." As the first Chinese female expert to join the SGBCC expert team, Dr. Yongmei Yin from Jiangsu Provincial Hospital initiated and promoted the "SGBCC China Tour" series to elevate global standards in breast cancer diagnosis and treatment, showcasing the strength of Chinese female experts. Oncology Frontier has invited Dr. Yongmei Yin to share her motivation behind organizing this series and her future plans.

Breast cancer is one of the most common malignancies among women globally, and continuous advancements in treatment modalities have brought new hope to many patients. At the 2024 SIBCS conference during the "Fourth 3C Summit Forum – Frontline Notes on the 2025 Breast Cancer Guideline Revision," Dr. Lei Fan from Fudan University Shanghai Cancer Center presented a report on the "Advances and Controversies in Adjuvant Therapy for Breast Cancer," discussing the latest research findings and controversies in adjuvant therapy for different breast cancer subtypes. This article provides a summary of Dr. Fan’s lecture for our readers.